A Agilent Technologies Inc.

Agilent Technologies Launches SureGuide CRISPR Libraries for Functional Genomics

Agilent Technologies Inc. (NYSE: A) today launched a comprehensive offering of pooled CRISPR libraries for functional genomics. SureGuide harnesses Agilent’s industry-leading oligonucleotide synthesis platform to create CRISPR guide libraries, which are a critical component of the CRISPR/Cas genome editing system. The flexibility of Agilent’s SureGuide platform enables CRISPR-based functional screening for any application, from genome-wide knock-outs (GeCKO) to fully customized, user-designed libraries.

The introduction of genome engineering tools, based on CRISPR, has rapidly accelerated research related to functional studies of complex diseases and drug discovery. Genetic screens using pooled libraries are typically performed to locate and identify genes that are involved in cellular response, such as in signaling pathways, or to discover the function of novel genes. The introduction of CRISPR-based tools has provided an opportunity to overcome the limitations of previous technologies used in functional screening.

As a key component in any CRISPR experiment, guide library quality and composition can affect all of the downstream segments of the workflow including screening effort, sequencing cost and false positive/negative identification. SureGuide offers high-fidelity CRISPR guides alongside SureVector cloning technology, which enable an optimal distribution of guides to be maintained across even the most complex libraries.

SureGuide CRISPR libraries are available in three formats:

Ready-to-package plasmid libraries consist of GeCKO libraries; target all exons in the human or mouse genome; and have been validated by researchers studying functional gene interactions on an -omics scale.

Ready-to-clone custom libraries enable user-defined custom CRISPR targets in mammalian cells. These custom libraries can be prepared for delivery with Agilent’s SureVector library cloning kits, which makes plasmid library generation a simple and rapid process.

Ready-to-amplify custom libraries enable researchers to design every aspect of their CRISPR library, allowing the use of alternative delivery systems, cloning approaches, and the development of CRISPR libraries targeting any set of genomic regions in any organism.

“Agilent SureGuide CRISPR Libraries are built on Agilent’s well known, high-fidelity oligo synthesis platform,” said Herman Verrelst, Agilent vice president and general manager, Genomics Solutions Division and Clinical Applications Division. “Our unique technology allows us to provide researchers with fully customizable guide libraries at the same exceptional quality as our GeCKO offerings.”

Verrelst noted that Agilent offers an extensive range of instrumentation and reagents that can help laboratories get the best possible results from their CRISPR screens.

“The new libraries represent the first of several planned products in a CRISPR-focused portfolio, supporting every aspect of the CRISPR screening workflow all the way through analysis and hit validation,” he said.

Agilent will host a workshop today at ASHG 2016 in Vancouver titled: A CRISPR Guide to Superior Custom sgRNA Libraries, where the SureGuide technology and workflow will be highlighted. In addition, customers will speak about their novel research applications using SureGuide CRISPR Libraries.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.

EN
20/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch